University of California San Diego
Welcome,         Profile    Billing    Logout  
 385 Trials 
1523 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Barshop, Bruce
NCT03897361: Stem Cell Gene Therapy for Cystinosis

Active, not recruiting
1/2
6
US
CTNS-RD-04 or CTNS-RD-04-LB (where the suffix "-LB" stands for LentiBOOST)
University of California, San Diego, California Institute for Regenerative Medicine (CIRM), Cystinosis Research Foundation
Lysosomal Storage Diseases, Cystinosis
11/24
11/24
Haas, Richard H
STRIDE, NCT04535609 / 2020-002855-40: An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients

Completed
2
213
Europe, Canada, US, RoW
Mavodelpar, REN001, Placebo
Reneo Pharma Ltd
Primary Mitochondrial Myopathy
09/23
10/23
NEOLEV3, NCT05610085: A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

Recruiting
2
133
US, RoW
Levetiracetam Injection, Phenobarbital Sodium Injection
University of California, San Diego, University of Minnesota, Rady Children's Hospital, San Diego, Auckland City Hospital, University of Auckland, New Zealand, Middlemore Hospital, New Zealand
Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Seizure Newborn
07/27
12/27
REVEAL, NCT05606614: Safety and Efficacy of TSHA-102 in Adolescent and Adult Females with Rett Syndrome ( Adult Study)

Recruiting
1/2
18
Canada, US
TSHA-102
Taysha Gene Therapies, Inc.
Rett Syndrome
01/25
01/32
NCT06152237: Safety and Efficacy of TSHA-102 in Pediatric Females with Rett Syndrome (REVEAL Pediatric Study)

Recruiting
1/2
20
Europe, Canada, US
TSHA-102
Taysha Gene Therapies, Inc.
Rett Syndrome
11/28
11/31
NAMDC, NCT01694940: North American Mitochondrial Disease Consortium Patient Registry and Biorepository

Recruiting
N/A
1000
Canada, US
Columbia University, National Institute of Neurological Disorders and Stroke (NINDS)
Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
12/25
12/25
Schiller, Gary J
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Exclusivity expiry in US
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT06401356: An Extension Study for Patients Previously Enrolled in Studies with Pelabresib

Recruiting
3
50
Europe, US
Pelabresib, CPI-0610
Constellation Pharmaceuticals
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
06/29
06/29
NCT04260698: Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Active, not recruiting
3
36
US
omidubicel, NiCord
Gamida Cell ltd
Hematological Malignancies
05/25
05/25
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
BP1001-201-AML, NCT02781883: Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Recruiting
2a
108
US
BP1001 in combination with Ventoclax plus decitabine, Liposomal Grb-2, L-Grb-2, BP1001 plus decitabine
Bio-Path Holdings, Inc.
Acute Myeloid Leukemia (AML)
12/24
12/24
NCT04231851: CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Active, not recruiting
2
30
US
Glasdegib, DAURISMO™, CPX-351, Daunorubicin and cytarabine, VYXEOS®
University of California, Irvine, Jazz Pharmaceuticals, Pfizer
Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
06/25
06/27
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML

Active, not recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
04/28
04/28
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
NCT06456463: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Recruiting
2
76
US, RoW
Tagraxofusp, Tag, Venetoclax, Ven, Azacitidine, Aza
Stemline Therapeutics, Inc.
Acute Myeloid Leukemia
02/28
02/30
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Active, not recruiting
2
196
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
09/25
10/27
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

Recruiting
2
9999
US
unlicensed CBU
New York Blood Center
Infusion Reactions
12/25
12/25
GRASP, NCT05353647: A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (, BMT CTN 2001)

Active, not recruiting
2
25
US
Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
David Williams, National Heart, Lung, and Blood Institute (NHLBI), California Institute for Regenerative Medicine (CIRM), bluebird bio, Blood and Marrow Transplant Clinical Trials Network
Sickle Cell Disease
05/26
05/26
Beat AML, NCT03013998: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Hourglass Jan 2023 - Mar 2023 : Data from Beat AML trial for acute myeloid leukemia
Recruiting
1/2
2000
US
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Enasidenib, Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), GS-9973, ENTO, Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), TAK-924, MLN4924, Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21)
Beat AML, LLC
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
12/26
12/26
KCP-8602-801, NCT02649790 / 2021-003810-38: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Checkmark From trial for myelodysplastic syndrome at ASH 2019
Dec 2019 - Dec 2019: From trial for myelodysplastic syndrome at ASH 2019
Active, not recruiting
1/2
277
Europe, Canada, US, RoW
KPT-8602, Eltanexor, ASTX727, Dexamethasone
Karyopharm Therapeutics Inc, Karyopharm Therapeutics Inc.
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
08/24
12/24
CADENZA, NCT03386513 / 2018-003210-40: Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Hourglass Jan 2024 - Dec 2024 : Top-line data from cohort 6 for 1L BPCDN
Active, not recruiting
1/2
179
Europe, US
IMGN632
AbbVie
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
09/23
12/26
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Hourglass Feb 2024 - Dec 2024 : Results from STOMP trial for RRMM and NDMM
Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with pomalidomide and dexamethasone for early line multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with pomalidomide and dexamethasone for early line multiple myeloma at ASH 2020
More
Recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
OPAL, NCT04329728: The Study: AVM0703 for Treatment of Lymphoid Malignancies

Recruiting
1/2
144
US
AVM0703, Supra-Pharmacologic Dexamethasone Phosphate
AVM Biotechnology Inc, Medpace, Inc.
Lymphoid Malignancies
04/25
06/25
NCT04774536: Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease

Recruiting
1/2
9
US
CRISPR_SCD001
Mark Walters, MD, University of California, Los Angeles, University of California, Berkeley
Sickle Cell Disease
03/27
03/29
NCT02247843: Stem Cell Gene Therapy for Sickle Cell Disease

Active, not recruiting
1/2
4
US
βAS3-FB vector transduced peripheral blood CD34+ cells, Lenti/βAS3-FB
Donald B. Kohn, M.D., California Institute for Regenerative Medicine (CIRM)
Sickle Cell Disease
12/25
12/25
NCT04536792: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Completed
1
122
Europe, US
AG-946, AG-946 Matched Placebo
Agios Pharmaceuticals, Inc.
Healthy Volunteers, Anemia, Sickle Cell
12/23
12/23
BP1002-102-AML, NCT05190471: A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Recruiting
1
48
US
BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Liposomal Bcl-2; L-Bcl-2, Decitabine (in combination with BP1002), Decitabine
Bio-Path Holdings, Inc.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
03/24
09/24
SENTI-202-101, NCT06325748: SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Recruiting
1
21
US, RoW
SENTI-202, Fludarabine, Cytarabine (ara-C)
Senti Biosciences
AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
09/25
08/40
NCT06226571: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Recruiting
1
76
US
SNDX-5613, Chemotherapy Regimen, HiDAC
Syndax Pharmaceuticals
Acute Myeloid Leukemias
02/27
02/27
CLN-049-001, NCT05143996: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Recruiting
1
60
US
CLN-049
Cullinan Oncology Inc.
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
08/25
11/25
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Lippman, Scott M
NCT02581137: Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

Active, not recruiting
2
26
Canada, US
Laboratory Biomarker Analysis, Metformin Hydrochloride, APO-Metformin, Cidophage, Dimefor, Glifage, Glucoformin, Glucophage, Glucophage ER, Metformin HCl, Riomet, Siofor
National Cancer Institute (NCI)
Erythroplakia, Hyperplasia, Oral Cavity Carcinoma, Oral Leukoplakia
10/17
12/25
NCT05237960: Metformin for the Prevention of Oral Cancer in Patients with Oral Leukoplakia or Erythroplakia

Recruiting
2
86
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Extended Release Metformin Hydrochloride, ER Metformin Hydrochloride, Extended-release Metformin Hydrochloride, Glucophage XR, Glumetza, Metformin Hydrochloride Extended Release, Placebo Administration
University of Arizona, National Cancer Institute (NCI)
Erythroplakia, Oral Leukoplakia
08/26
08/28
Cohen, Ezra
NCT02769520: Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

Active, not recruiting
2
27
US
Pembrolizumab, Keytruda
Assuntina Sacco, M.D., Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of the Head and Neck
04/25
04/26
NCT03795610: Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

Recruiting
2
15
US
IPI-549
Ezra Cohen, The V Foundation for Cancer Research
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancer Stage III, HPV-Related Carcinoma, HPV-Related Malignancy, HPV-Related Squamous Cell Carcinoma
06/23
06/23
KEYNOTE-D38, NCT05077709: IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Active, not recruiting
2
63
Europe, US
IO102-IO103 in combination with pembrolizumab
IO Biotech, Theradex, Almac, NeoGenomics, Merck Sharp & Dohme LLC
Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
01/24
11/24
NCI-2018-01227, NCT03603223: Pembrolizumab in Treating Participants with Leukoplakia

Recruiting
2
26
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Jonsson Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Erythroleukoplakia, Leukoplakia, Verrucous Oral Leukoplakia
08/25
08/26
NCT05074940: Amivantamab in Adenoid Cystic Carcinoma

Recruiting
2
18
US
Amivantamab
Trisha Wise-Draper
Salivary Gland Cancer
08/24
08/28
PEMDA-HN, NCT05814666: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Recruiting
2
81
Europe, US, RoW
Danvatirsen, ISIS 481464, AZD9150, Pembrolizumab, Keytruda
Flamingo Therapeutics NV
HNSCC
05/25
05/26
NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Withdrawn
2
130
Europe, US, RoW
RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab
Replimune Inc., Bristol-Myers Squibb
Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
03/26
06/26
NCT04020185: Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Completed
1/2
40
US
IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy
ImmuneSensor Therapeutics Inc.
Solid Tumor, Adult
09/23
09/23
NCT05153304: Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers

Withdrawn
1/2
20
US
personalized vaccine, Nivolumab, Opdivo
University of California, San Diego
Cancer of Gastrointestinal Tract
06/26
06/27
NCT03991741: Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Recruiting
1
24
US
Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
Gregory Daniels, Immunotherapy Foundation
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
08/24
08/26
NCT02418442: Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

Recruiting
N/A
20000
Europe, Canada, US, RoW
Duke University, Childhood Arthritis and Rheumatology Research Alliance
Rheumatic Joint Disease
06/28
12/28
Ilfeld, Brian M
NCT04558281: Continuous Erector Spinae Plane Blocks for Rib Fractures

Terminated
4
4
US
Active ropivacaine 0.3% erector spinae plane perineural administration, Placebo erector spinae plane perineural administration
University of California, San Diego
Rib Fractures, Trauma, Anesthesia, Anesthesia, Local
03/22
03/23
NCT04198662: Rib Fracture Analgesia Using Cryoanalgesia

Completed
4
20
US
Cryoneurolysis with a Painblocker (Epimed International, Farmers Branch, Texas), Intercostal nerve block ropivacaine with epinephrine, Sham cryoneurolysis with a Painblocker, Placebo intercostal nerve block with normal saline
University of California, San Diego
Traumatic Rib Fracture(s)
08/23
08/24
NCT04742309: Pectoralis Block vs Paravertebral Nerve Blocks for Breast Surgery

Completed
4
119
US
Pecs-2 block (single injection), Paravertebral block (single injection)
University of California, San Diego
Breast Surgery
08/23
08/23
NCT05091905: Patient-Titrated Automated Intermittent Boluses of Local Anesthetic vs. a Continuous Infusion Via a Perineural Catheter for Postoperative Analgesia

Enrolling by invitation
4
140
US
Continuous Infusion of ropivacaine 0.2%, Perineural local anesthetic infusion, Titratable Automated Intermittent Boluses of ropivacaine 0.2%, Perineural local anesthetic administration
University of California, San Diego
Pain, Acute Postoperative, Trauma Injury
11/26
12/26
NCT03461120: Improving Postamputation Functioning by Decreasing Phantom Pain With Perioperative Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study

Enrolling by invitation
4
203
US
Experimental continuous peripheral nerve blocks, Experimental perineural local anesthetic infusion, Control continuous peripheral nerve blocks, Control perineural local anesthetic infusion
University of California, San Diego, United States Department of Defense, United States Naval Medical Center, San Diego, The Cleveland Clinic, Walter Reed National Military Medical Center, Johns Hopkins University, Wake Forest Medical Center, Boston VA, Mass. General Hospital, Brigham and Women's Hospital
Lower Extremity Surgical Amputation, Post-amputation Phantom Limb Pain
03/26
06/26
NCT05121168: Continuous Erector Spinae Plane Blocks to Treat Pain Following Percutaneous Nephrolithotomy

Enrolling by invitation
4
50
US
Active bupivacaine 0.25% via an erector spinae plane perineural catheter, Placebo normal saline via an erector spinae plane perineural catheter
University of California, San Diego
Pain, Acute Postoperative, Renal Stone
12/25
12/26
NCT03578237: Cryoanalgesia to Prevent Acute and Chronic Pain Following Surgery: A Randomized, Double-Masked, Sham-Controlled Study

Completed
N/A
99
US
Cryoneurolysis (active), Sham cryoneurolysis procedure, Placebo treatment
University of California, San Diego, Epimed International, Myoscience (prior to merger with Pacira Pharmaceuticals)
Mastectomy, Upper Limb Amputation Below Elbow, Upper Limb Amputation Above Elbow, Lower Limb Amputation Below Knee, Lower Limb Amputation Above Knee, Knee Arthropathy, Shoulder Arthroplasty, Rotator Cuff Repair, Video-Assisted Thoracoscopic Surgery (VATS), Skin Grafting
01/22
11/22
NCT05392803: Pulsed Electromagnetic Fields for Post-Amputation Pain

Completed
N/A
14
US
Active then Sham Treatment, nonthermal, pulsed shortwave (radiofrequency) therapy then sham, pulsed electromagnetic fields therapy then sham, Sham then Active Treatment, Sham then nonthermal, pulsed shortwave (radiofrequency) therapy, Sham then pulsed electromagnetic fields therapy
University of California, San Diego
Phantom Limb Pain, Residual Limb Pain
08/23
08/23
NCT05399355: Pulsed Electromagnetic Fields for Postoperative Analgesia: A Randomized, Triple-Masked, Sham-Controlled Pilot Study

Completed
N/A
119
US
Active Pulsed Shortwave Treatment with BioElectronics Model 088, nonthermal, pulsed shortwave (radiofrequency) therapy, pulsed electromagnetic fields therapy, Sham Treatment, Placebo treatment
University of California, San Diego
Postoperative Pain, Acute
10/23
04/24
NCT05521516: Percutaneous Auricular Neuromodulation for Postoperative Analgesia

Completed
N/A
120
US
Active Percutaneous Auricular Neuromodulation with NSS-2 Bridge, Sham Treatment, Placebo
University of California, San Diego
Postoperative Pain, Acute
12/24
12/24
NCT04341948: Treatment of Post-Operative Pain Following Orthopedic Surgery With SPRINT® Peripheral Nerve Stimulation (PNS) System

Completed
N/A
56
US
SPRINT Peripheral Nerve Stimulation (PNS) System, SPRINT, SPRINT System
SPR Therapeutics, Inc., United States Department of Defense
Postoperative Pain, Total Knee Replacement, Total Knee Arthroplasty, Partial Knee Replacement
06/24
06/24
NCT04713098: Ultrasound-Guided Percutaneous Peripheral Nerve Stimulation: A Department of Defense Funded Pragmatic Clinical Trial

Enrolling by invitation
N/A
250
US
Peripheral Nerve Stimulation, SPR Therapeutics, Sham
University of California, San Diego, Congressionally Directed Medical Research Programs
Rotator Cuff Repair, Ankle Arthroplasty or Arthrodesis, Hallux Valgus (Bunion) Resection
10/24
10/25
NCT06071715: Cryoanalgesia to Treat Phantom Limb Pain Following Above-Knee Amputation

Active, not recruiting
N/A
12
US
ACTIVE cryoneurolysis, cryoablation, SHAM cryoneurolysis, sham cryoablation
University of California, San Diego, Varian Medical Systems
Amputation, Surgical, Amputation, Traumatic, Phantom Limb Pain, Phantom Pain Following Amputation of Lower Limb
11/24
10/25
NCT06069154: Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Pain Following Thoracic Trauma

Enrolling by invitation
N/A
120
US
Cryoneurolysis, cryoablation, Local anesthetic peripheral nerve block, Sham Cryoneurolysis, sham cryoablation, Sham peripheral nerve block
University of California, San Diego, Congressionally Directed Medical Research Programs
Rib Fracture, Rib Fracture Multiple
03/26
01/27
Burns, Jane L
NCT02179853: Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease

Completed
1/2
22
US
Anakinra, Kineret
University of California, San Diego, Boston Children's Hospital, Cedars-Sinai Medical Center
Kawasaki Disease
10/22
12/22
NCT04747847: Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease

Active, not recruiting
1
10
US
Atorvastatin and anakinra
University of California, San Diego, National Heart, Lung, and Blood Institute (NHLBI)
Kawasaki Disease
11/24
04/25
NCT04538495: Characterization of Multisystem Inflammatory Syndrome in Children (MIS-C) and Its Relationship to Kawasaki Disease

Recruiting
N/A
100
US
University of California, San Diego
Kawasaki Disease, Inflammation
08/21
12/21
Monga, Manoj
NCT02375295: Struvite Stones Antibiotic Study

Recruiting
4
28
Canada, US
ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin, Keflex, Macrobid, co-trimoxazole
University of British Columbia
Kidney Stones
12/23
12/23
CoLUM, NCT04069338: Comparison of Lithotripsy Urolithiasis Machines

Completed
N/A
6
US
Lithotripter
The Cleveland Clinic
Kidney Stone, Kidney Calculi, Ureteral Calculi, Ureterolithiasis, Urolithiasis
10/22
10/22
NCT04767919: MIP Versus PCNL for Kidney Stone Disease

Recruiting
N/A
90
Canada, US
Standard Percutaneous Nephrolithotomy (sPCNL), Minimally Invasive Percutaneous Nephrolithotomy (MIP)
University of California, San Diego
Kidney Stone
01/23
01/23
NCT04069013: Standard vs Mini-PCNL for the Treatment of Stone Disease

Recruiting
N/A
90
US
PCNL
The Cleveland Clinic, University of British Columbia, Massachusetts General Hospital, Vanderbilt University Medical Center, Duke University, Ohio State University, Columbia University, Dartmouth-Hitchcock Medical Center
Urolithiasis, Kidney Stone, Kidney Calculi, Ureteral Calculi, Kidney Diseases
12/24
12/24
URIPRENE, NCT04565795: Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy

Recruiting
N/A
87
US
Uriprene® Degradable Temporary Ureteral Stent
Adva-Tec, Northwest Clinical Research Group
Ureteral Diseases
06/25
12/25
Medeiros, Felipe
NCT03318549: BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases

Completed
N/A
115
US
Visual Performance tests, Brain-computer interface
University of Miami, National Eye Institute (NEI)
Glaucoma, Macular Degeneration, Glaucoma Suspect, Optic Neuropathy, Retinal Degeneration, Visual Pathway Disorder
05/23
05/23
Butler, Lisa D
TALS LB, NCT05137665: Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

Recruiting
N/A
1000
US, RoW
Target ALS Foundation, Inc.
Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease
12/31
12/31
Neul, Jeffrey L
NCT06152237: Safety and Efficacy of TSHA-102 in Pediatric Females with Rett Syndrome (REVEAL Pediatric Study)

Recruiting
1/2
20
Europe, Canada, US
TSHA-102
Taysha Gene Therapies, Inc.
Rett Syndrome
11/28
11/31
NCT05932589: Neurophysiologic Biomarkers in Rett Syndrome

Recruiting
N/A
202
US
EEG and Auditory and Visual Evoked Potentials (AEP and VEP), Clinical assessment
Children's Hospital of Philadelphia, National Institute of Neurological Disorders and Stroke (NINDS), Vanderbilt University Medical Center
Rett Syndrome, RTT, Rett Syndrome, Atypical
03/28
03/29
Duleba, Antoni J
NCT06450405: Androgen Effects on the Reproductive Neuroendocrine Axis

Recruiting
4
60
US
Testosterone Cypionate 50 MG/ML Injectable Solution, Testosterone Replacement Therapy
University of California, San Diego, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Transgenderism, Reproductive Issues
11/28
11/28
Wetherell, Julie
NCT06704061: Online Yoga vs Acceptance and Commitment Therapy for Treating Chronic Musculoskeletal Pain

Not yet recruiting
N/A
274
US
Yoga, Acceptance and Commitment Therapy (ACT)
Palo Alto Veterans Institute for Research
Chronic Pain, Musculoskeletal Pain
07/29
07/29
Feifel, David
uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting
3
240
US
Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support
Usona Institute, Worldwide Clinical Trials
Depressive Disorder, Major
04/25
04/26
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Recruiting
3
255
US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/25
02/26
NCT05733546: A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Recruiting
2
102
US
Psilocybin, COMP360
COMPASS Pathways
Major Depressive Disorder
10/24
11/24
NCT04279522: The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)

Completed
N/A
126
US, RoW
Relivion®DP- Active, Relivion®DP- Sham
Neurolief Ltd.
MDD
06/24
06/24
Litvan, Irene
EIP21-NFD-504, NCT05869669: RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Active, not recruiting
2
160
Europe, US
Neflamapimod, VX-745, Placebo
EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc
Dementia With Lewy Bodies
08/24
03/25
4RTNI-2, NCT02966145: 4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

Active, not recruiting
N/A
232
Canada, US
Observational Study
University of California, San Francisco, National Institutes of Health (NIH), National Institute on Aging (NIA)
Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)
12/24
12/24
PDGENE, NCT04057794: PDGeneration: Mapping the Future of Parkinson's Disease

Active, not recruiting
N/A
1982
US
Lab Assay for seven genetic variants for Parkinson's Disease
Parkinson's Foundation, Fulgent Laboratories, Indiana University, The Parkinson Study Group, Navitas Clinical Research, Inc
Parkinson's Disease and Parkinsonism
12/21
04/25
NCT04363684: ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Recruiting
N/A
2100
Canada, US
Mayo Clinic, University of California, San Francisco, National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS)
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
06/25
06/25
NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry

Recruiting
N/A
25000
Canada, US, RoW
Lab Assay for seven genetic variants for Parkinson's Disease
Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group
Parkinson's Disease
12/24
06/25
NCT04735627: Real-Time Levodopa Level Monitoring in Parkinson Disease

Recruiting
N/A
20
US
Levodopameter
University of California, San Diego
Parkinson Disease
12/27
02/28
Strong, David
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1040
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
06/26
09/26
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
250
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
06/25
09/25
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
275
US, RoW
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT06124807: A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
179
US, RoW
LY3305677, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
01/25
05/25
EMPACT-Us, NCT05750537: Enhanced Multicomponent Proactive Navigator-Assisted Cessation of Tobacco Use in Low-Income Patients

Recruiting
N/A
13496
US
EMPACT-Us
Family Health Centers of San Diego, University of California, San Diego, Tobacco Related Disease Research Program
Tobacco Use Cessation
06/25
06/25
Kaye, Walter
NCT05481736: Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

Completed
2
32
Europe, US
Psilocybin, COMP360
COMPASS Pathways
Anorexia Nervosa
11/24
11/24
Reid, Erin G
NCT04305691: Trial of Ixazomib for Kaposi Sarcoma

Recruiting
2
41
US
Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
AIDS Malignancy Consortium, National Cancer Institute (NCI)
Kaposi Sarcoma, Skin
05/25
05/26
NCT04577755: Pomalidomide Treatment in Patients With Kaposi Sarcoma

Recruiting
2
45
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Pomalidomide, 4-Aminothalidomide, Actimid, CC 4047, CC-4047, CC4047, Imnovid, Pomalyst, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Skin Kaposi Sarcoma
03/26
03/26
NCT03893682: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Active, not recruiting
1
160
US
CG-806, Luxeptinib
Aptose Biosciences Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
12/24
05/25
NCT04949464: Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study

Recruiting
N/A
100
US
Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Smoking Cessation Intervention, Smoking and Tobacco Use Cessation Interventions
AIDS Malignancy Consortium, National Cancer Institute (NCI)
HIV Infection, Tobacco-Related Carcinoma
05/25
05/26
NCT05510908: Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

Recruiting
N/A
720
US
Non-Interventional, Non-Interventional Follow-up
AIDS Malignancy Consortium, National Cancer Institute (NCI)
HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma, AIDS-related Kaposi Sarcoma, AIDS-Related Malignancy, Anal Cancer, HPV-Related Malignancy
11/25
09/26
Wachsman, William
NCT02799485: sEphB4-HSA in Treating Patients With Kaposi Sarcoma

Active, not recruiting
2
23
US
Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA
AIDS Malignancy Consortium, National Cancer Institute (NCI), Vasgene Therapeutics, Inc, The Emmes Company, LLC, University of Arkansas
Skin Kaposi Sarcoma
12/25
06/26
Cadenhead, Kristin
NCT04411225: Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

Recruiting
3
120
US
Cannabidiol oral solution, Placebo
University of California, San Diego, Center for Medicinal Cannabis Research
Early Psychosis
06/25
10/25
NCT02245607: Compensatory Cognitive Training in Clinical High Risk Latino Youth

Active, not recruiting
N/A
120
US, RoW
Compensatory Cognitive Training, Recreational Therapy
University of California, San Diego, National Institute of Mental Health (NIMH)
Clinical High Risk, Psychosis, Prodromal, Schizophrenia
06/20
02/21
NCT04338152: Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial

Active, not recruiting
N/A
220
Canada, US
Family Focused Therapy for Clinical High Risk Youth (FFT-CHR), Enhanced Care (EC)
University of California, Los Angeles, National Institute of Mental Health (NIMH)
Psychotic Disorders, Prodromal Symptoms, Prodromal Schizophrenia, Psychosis, Family
06/26
12/26
Dransfield, Mark
NCT06376994: Multi-Center Clean Air Randomized Controlled Trial in COPD

Recruiting
3
770
US
Air cleaner, Sham air cleaner
JHSPH Center for Clinical Trials, National Heart, Lung, and Blood Institute (NHLBI)
Chronic Obstructive Pulmonary Disease (COPD)
09/27
09/28
 

Download Options